US EditionPublished • loading... • Updated
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
- This year, Novo Nordisk narrowed its guidance after lowering growth expectations for GLP-1 treatments, reporting a quarter net profit of 20 billion Danish kroner.
- Rising competition and U.S. pricing pressures prompted the company to lower growth expectations, citing prescription trends and transformation with DKK 95.9 billion restructuring costs affecting outlooks.
- Robust year-to-date sales coexist with softer near-term growth expectations for GLP-1 medicines, with Diabetes & Obesity sales at DKK 215.7 billion driven by 37% growth in Obesity care to DKK 59.9 billion.
- Investors have punished the stock, with shares falling more than 50% this year, while the Board called an EGM to elect new board members accessible via the investor link.
- Meanwhile, the company is adding assets—agreeing to buy Akero and cagrilintide, and secured Wegovy MASH approval, while Pfizer filed a lawsuit alleging anticompetitive conduct.
Insights by Ground AI
15 Articles
15 Articles
Danish diet giant Novo Nordisk is once again failing to live up to expectations.
·Stockholm, Sweden
Read Full Article
Coverage Details
Total News Sources15
Leaning Left2Leaning Right1Center8Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
L 18%
C 73%
Factuality
To view factuality data please Upgrade to Premium
